ReviewCritical reviews in immunology2000
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
Review in Critical reviews in immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 72 citations in OpenAlex.
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.Cancer immunology, immunotherapy : CII · 2016Trial
- Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Review
- A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.Cellular & molecular immunology · 2018Article
- Human αβ and γδ T Cells in Skin Immunity and Disease.Frontiers in immunology · 2018Review
- Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.Nanomedicine (London, England) · 2017Review
- Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8Clinical & translational immunology · 2017Article
- Novel vaccines for glioblastoma: clinical update and perspective.Immunotherapy · 2016Review
- Melanoma-associated leukoderma - immunology in black and white?Pigment cell & melanoma research · 2013Review
- Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology · 2013Review
- Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.Molecular and clinical oncology · 2013Article
- HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.Journal of Cancer · 2013Article
- Adoptive immunotherapy for cancer: harnessing the T cell response.Nature reviews. Immunology · 2012Review
- Article
- Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.Cancer immunology, immunotherapy : CII · 2010Article
- Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2009Article
- Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.Cancer immunology, immunotherapy : CII · 2008Article
- Therapeutic implications of autoimmune vitiligo T cells.Autoimmunity reviews · 2006Review
- Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.The Journal of clinical investigation · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It is increasingly clear that immunity to "self"-antigens may result in tumor destruction in mouse and man. But which antigens should be targeted with therapeutic cancer vaccines? In the case of melanoma, recognition of melanocyte differentiation antigens (MDA) can be associated with autoimmune depigmentation (vitiligo). We propose that intersection of protein transport to melanosomes and endosomes allows for the loading of MDA-derived peptides on MHC class II molecules, resulting in the activation of MDA-specific CD4+ "helper" T cells that aid the induction of melanoma-specific CD8+ T cells. Thus, the immunogenicity of MDA may be a consequence of their unique cell biology. Studies of MDA-based vaccines can provide new insight into the development of more effective cancer vaccines.
Indexed as
Identifiers
11396680PMC2543120W2085687864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.